Eli Lilly Lifts Forecast as Demand for Weight-Loss Drugs Stays Strong
Eli Lilly has raised its full-year sales and profit forecast after seeing strong, ongoing demand for its popular weight-loss and diabetes drugs. The company said prescriptions for its blockbuster medicine Zepbound, and its diabetes version Mounjaro, continue to surge. Both drugs use the same active ingredient and have become major drivers of growth in the…